MX2015011438A - Procedimiento para preparar compuestos benzoxazepina. - Google Patents
Procedimiento para preparar compuestos benzoxazepina.Info
- Publication number
- MX2015011438A MX2015011438A MX2015011438A MX2015011438A MX2015011438A MX 2015011438 A MX2015011438 A MX 2015011438A MX 2015011438 A MX2015011438 A MX 2015011438A MX 2015011438 A MX2015011438 A MX 2015011438A MX 2015011438 A MX2015011438 A MX 2015011438A
- Authority
- MX
- Mexico
- Prior art keywords
- making
- benzoxazepin compounds
- compounds
- making benzoxazepin
- gdc
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical class O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 title 1
- 239000012828 PI3K inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779619P | 2013-03-13 | 2013-03-13 | |
| PCT/EP2014/054786 WO2014140073A1 (en) | 2013-03-13 | 2014-03-12 | Process for making benzoxazepin compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015011438A true MX2015011438A (es) | 2016-02-03 |
Family
ID=50241450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011438A MX2015011438A (es) | 2013-03-13 | 2014-03-12 | Procedimiento para preparar compuestos benzoxazepina. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9303043B2 (enExample) |
| EP (3) | EP2970329A1 (enExample) |
| JP (6) | JP6363120B2 (enExample) |
| KR (3) | KR20180070715A (enExample) |
| CN (2) | CN105377856B (enExample) |
| AR (1) | AR095365A1 (enExample) |
| AU (3) | AU2014230812B2 (enExample) |
| BR (1) | BR112015020716A2 (enExample) |
| CA (6) | CA2897618A1 (enExample) |
| IL (1) | IL240793A0 (enExample) |
| MX (1) | MX2015011438A (enExample) |
| NZ (1) | NZ711192A (enExample) |
| RU (2) | RU2018109979A (enExample) |
| SG (2) | SG10201706760YA (enExample) |
| WO (1) | WO2014140073A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266903B2 (en) * | 2013-12-16 | 2016-02-23 | Genentech, Inc. | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazole-5-yl)-5,6-dihydrobenzo[F]imidazo [1,2-D][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
| CN111909173B (zh) * | 2015-07-02 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法 |
| JP6522807B2 (ja) | 2015-07-02 | 2019-05-29 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法 |
| CN105906635A (zh) * | 2016-06-08 | 2016-08-31 | 上海大学 | 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法 |
| EP3492452B1 (en) * | 2016-07-29 | 2022-08-31 | Japan Tobacco Inc. | Production method for pyrazole-amide compound |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| PL3851441T3 (pl) | 2016-12-15 | 2023-11-06 | F. Hoffmann-La Roche Ag | Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu |
| CN108752237A (zh) * | 2018-07-05 | 2018-11-06 | 四川青木制药有限公司 | 一种对氨基苯甲脒盐酸盐的新制备方法 |
| BR112021011894A2 (pt) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
| US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| ES2205944T3 (es) * | 1998-10-23 | 2004-05-01 | Dow Agrosciences Llc | Compuestos de 3-(fenil sustituido)-5-(ciclopropil sustituido)-1,2,4-triazol. |
| HUP0400164A2 (hu) | 2001-07-12 | 2004-07-28 | Avecia Ltd. | Mikrokapszulázott katalizátor, eljárás előállítására és alkalmazása |
| CA2463441A1 (en) * | 2001-10-12 | 2003-05-08 | Bayer Pharmaceuticals Corporation | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity |
| EP1945222B1 (en) | 2005-11-02 | 2012-12-26 | Bayer Pharma Aktiengesellschaft | Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| EA016527B1 (ru) * | 2006-10-23 | 2012-05-30 | ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. | Триазолопиридазиновые модуляторы протеинкиназ |
| BRPI0717320A2 (pt) * | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Triazóis bicíclicos como moduladores de proteína cinase |
| CA2675755C (en) * | 2007-01-19 | 2015-10-06 | Xcovery, Inc. | Pyridine and pyridazine derivatives as kinase inhibitors |
| WO2009055730A1 (en) * | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| CN102015693B (zh) * | 2008-02-21 | 2014-10-29 | 默沙东公司 | 作为erk抑制剂的化合物 |
| ES2480994T3 (es) | 2008-03-31 | 2014-07-29 | Genentech, Inc. | Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| US8263633B2 (en) | 2009-09-28 | 2012-09-11 | F. Hoffman-La Roche Ag | Benzoxepin PI3K inhibitor compounds and methods of use |
| TWI423980B (zh) * | 2009-09-28 | 2014-01-21 | Hoffmann La Roche | 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法 |
| CA2778684A1 (en) * | 2009-10-29 | 2011-05-05 | Schering Corporation | Bridged bicyclic piperidine derivatives and methods of use thereof |
| CN102558167A (zh) * | 2010-12-29 | 2012-07-11 | 中国医学科学院药物研究所 | Gk和ppar双重激动活性的噻唑烷二酮衍生物 |
| KR20140032383A (ko) | 2011-03-21 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법 |
| NO3175985T3 (enExample) * | 2011-07-01 | 2018-04-28 | ||
| CN104379163A (zh) | 2012-06-08 | 2015-02-25 | 霍夫曼-拉罗奇有限公司 | 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合 |
-
2014
- 2014-03-12 US US14/205,634 patent/US9303043B2/en active Active
- 2014-03-12 AR ARP140100904A patent/AR095365A1/es unknown
- 2014-03-12 BR BR112015020716A patent/BR112015020716A2/pt not_active Application Discontinuation
- 2014-03-12 CA CA2897618A patent/CA2897618A1/en not_active Abandoned
- 2014-03-12 CA CA2948763A patent/CA2948763C/en not_active Expired - Fee Related
- 2014-03-12 CA CA3005103A patent/CA3005103A1/en not_active Abandoned
- 2014-03-12 RU RU2018109979A patent/RU2018109979A/ru not_active Application Discontinuation
- 2014-03-12 KR KR1020187016976A patent/KR20180070715A/ko not_active Withdrawn
- 2014-03-12 CA CA3005118A patent/CA3005118A1/en not_active Abandoned
- 2014-03-12 RU RU2015138488A patent/RU2649976C2/ru not_active IP Right Cessation
- 2014-03-12 SG SG10201706760YA patent/SG10201706760YA/en unknown
- 2014-03-12 EP EP14709314.0A patent/EP2970329A1/en not_active Withdrawn
- 2014-03-12 JP JP2015562108A patent/JP6363120B2/ja active Active
- 2014-03-12 EP EP18173513.5A patent/EP3404032B1/en active Active
- 2014-03-12 AU AU2014230812A patent/AU2014230812B2/en not_active Ceased
- 2014-03-12 EP EP20204345.1A patent/EP3845540B1/en active Active
- 2014-03-12 WO PCT/EP2014/054786 patent/WO2014140073A1/en not_active Ceased
- 2014-03-12 KR KR1020177016062A patent/KR101871133B1/ko not_active Expired - Fee Related
- 2014-03-12 CN CN201480015055.8A patent/CN105377856B/zh active Active
- 2014-03-12 CA CA2948765A patent/CA2948765A1/en not_active Abandoned
- 2014-03-12 CA CA3005112A patent/CA3005112A1/en not_active Abandoned
- 2014-03-12 MX MX2015011438A patent/MX2015011438A/es unknown
- 2014-03-12 NZ NZ711192A patent/NZ711192A/en not_active IP Right Cessation
- 2014-03-12 SG SG11201507394RA patent/SG11201507394RA/en unknown
- 2014-03-12 CN CN201810489045.8A patent/CN108929333A/zh active Pending
- 2014-03-12 KR KR1020157024484A patent/KR101821468B1/ko not_active Expired - Fee Related
-
2015
- 2015-08-24 IL IL240793A patent/IL240793A0/en unknown
-
2016
- 2016-06-28 AU AU2016204432A patent/AU2016204432B2/en not_active Ceased
-
2017
- 2017-07-10 JP JP2017135083A patent/JP6442005B2/ja active Active
-
2018
- 2018-02-27 AU AU2018201393A patent/AU2018201393A1/en not_active Abandoned
- 2018-03-12 JP JP2018044050A patent/JP2018150298A/ja active Pending
- 2018-08-16 JP JP2018153231A patent/JP6663459B2/ja active Active
- 2018-11-22 JP JP2018219226A patent/JP2019089762A/ja active Pending
-
2020
- 2020-02-28 JP JP2020032846A patent/JP2020114814A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ711192A (en) | Process for making benzoxazepin compounds | |
| PH12018501094A1 (en) | Process for the preparation of an apoptosis-inducing agent | |
| PH12016500676B1 (en) | Pyrimidine fgfr4 inhibitors | |
| PH12015502248A1 (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
| PH12016501192A1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| NZ726859A (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
| MX349548B (es) | Compuestos de tienopirimidina. | |
| MX2015013589A (es) | Proceso e intermediario para la preparacion de pregabalina. | |
| CY1121116T1 (el) | Νεα μεθοδος για την συνθεση αγομελατινης | |
| NZ720106A (en) | A process for the preparation of regadenoson | |
| GB201107985D0 (en) | Process | |
| IN2013MU01113A (enExample) | ||
| MY191759A (en) | Processes for the preparation of pyrimidinylcyclopentane compounds | |
| WO2014177978A3 (en) | An improved process for the preparation of teriflunomide | |
| MX2015012523A (es) | Metodos para elaborar composiciones antineoplasicas. | |
| MX2016000487A (es) | Piridina-2-carboxamidas como nematicidas. | |
| MX391523B (es) | Intermediarios y metodos para sintetizar derivados de calicheamicina | |
| IN2013MU01219A (enExample) | ||
| MX2016005220A (es) | Tinturas acidas, proceso para su produccion y su uso. | |
| IN2013MU01524A (enExample) | ||
| IN2013DE03592A (enExample) | ||
| MX2016005221A (es) | Tinturas acidas, proceso para su produccion y su uso. | |
| IN2014MU00069A (enExample) | ||
| UA91886U (uk) | 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол |